{\rtf1\ansi\ansicpg1252\cocoartf949\cocoasubrtf430
{\fonttbl\f0\froman\fcharset0 TimesNewRomanPSMT;\f1\fswiss\fcharset0 ArialMT;}
{\margl1800\margr1600\margt500\margbl1440}
{\pard\sa900\fs50\f0\i Media Release\par}
{\pard\f0\li0\ri0\sa360\sl360\fs22 Basel, 15 November 2004\line \line {\b Opening 
of new 
HIV Centre in Cambodia signifies further progress in efforts to tackle HIV/AIDS} \line Unique 
collaboration supported by Roche signifies further achievement in increasing access to HIV/AIDS treatment 
and care\line \line The Cambodia Treatment Access Programme (CTAP) has provided 
support for a new treatment centre for people living with HIV/AIDS in the capital, Phnom Penh, as part 
of its on-going efforts to tackle the growing problem of HIV/AIDS. Cambodia currently has the highest 
recorded HIV prevalence in Asia{\super {\pard\f0\li0\ri0\sa360\sl360\fs18 1\par}} , with 
over 170,000 people currently living with HIV/AIDS{\super {\pard\f0\li0\ri0\sa360\sl360\fs18 2\par}} . 
\line \line CTAP, 
which was established in September 2003, is a three-way partnership between:\par}{\pard\f0\li440\ri0\sl360\fs22 - The 
Cambodian 
Ministry of Health\par}{\pard\f0\li440\ri0\sl360\fs22 - The National Centre in HIV Epidemiology and 
Clinical Research at 
the University of New South Wales, Australia\par}{\pard\f0\li440\ri0\sl360\fs22 - Roche\par}\line {\pard\f0\li0\ri0\sa360\sl360\fs22 This 
public-private partnership is one of a number of activities being supported by Roche in resource-poor 
settings as part of its commitment to increasing access to HIV/AIDS healthcare.\line \line William 
M. Burns, Head of Roche Pharmaceuticals said: \u8220?This is a unique collaboration established to increase 
access to vital HIV/AIDS healthcare in Cambodia, conduct research, and train local healthcare professionals. 
Roche is committed to helping people in greatest need by working in partnership with others, ensuring 
expertise is shared and removing patents and profit as barriers to our HIV protease inhibitor medicines 
in Least Developed Countries. This project is one of our efforts to make a long term difference in the 
fight against HIV/AIDS.\u8221? \line \line {\b CTAP \u8211? Phnom Penh}  \line The 
new treatment centre has been established to provide a range of services including counseling, clinical 
care, preventative treatment for opportunistic infections and HIV therapy, and has been designed to 
provide the framework for a comprehensive programme of training and research in HIV medicine.\line \line Dr 
Mean Chhi Vun, Director of the Cambodian National Center for HIV/AIDS, Dermatology and STDs (NCHADS) 
comments: \u8220?Everyone involved in CTAP has played a vital role in establishing the centre and developing 
the treatment and training programmes. This is a real achievement that we hope will have a great impact 
on people living with HIV/AIDS in Cambodia. Addressing the problems of HIV/AIDS is a real challenge 
and it is essential that activities undertaken focus on the needs of our people living with HIV/AIDS 
now and in the future. The commitment and support of Roche in helping us to establish a programme that 
is sustainable and can have long-term benefits will make a real difference to the people of Cambodia\u8221?. 
\line \line {\b Achievements of CTAP} \line In addition 
to the opening of the 
HIV centre, the work undertaken by the partnership has already had an impact on HIV/AIDS in Cambodia. 
To date, CTAP has played a role in the:\par}{\pard\f0\li440\ri0\sl360\fs22 - Development 
and publication of Cambodian National 
HIV treatment Guidelines and Policies\par}{\pard\f0\li440\ri0\sl360\fs22 - Development of a National 
HIV Care Training Programme 
to help expand access to quality HIV care throughout the country\par}\line {\pard\f0\li0\ri0\sa360\sl360\fs22 Also, 
NCHADS and UNSW staff supported by CTAP played key roles in helping secure monies for Cambodia from 
the {\i Global Fund for AIDS, tuberculosis and malaria} . An application for fourth 
round funding for HIV 
treatment and care was successful, with a total of US $36.5m being secured for disbursement over the 
next five years. It is estimated that this funding will enable coverage of HIV treatment to be scaled 
up to 75 per cent of those in need to treatment in Cambodia. \line \line David Cooper, 
Director of The National Centre in HIV Epidemiology and Clinical Research at the University of New South 
Wales (UNSW), Australia, comments: \u8220?Since the beginning of the partnership, CTAP has made real advances 
in the area of HIV/AIDS in Cambodia, with the training of local healthcare professionals and our contribution 
to the National HIV programs highlighting our achievements. In establishing the clinic, we have faced 
a number of challenges, but with the hard work of everyone involved and the strong commitment the Cambodian 
Government and Roche we have overcome these challenges and are very proud to be welcoming the first 
patients into the clinic.\u8221? \line \line In addition to the vital contribution for 
CTAP, Roche supports other treatment access programmes, such as the CARE programme in four African countries. 
CARE is the Cohort programme to evaluate Access to antiretRoviral treatment and Education. The programme 
is run in four major urban treatment centres, C\u244?te d\u8217?Ivoire, Kenya, Senegal and Uganda. To date, 24-week 
results have shown that treatment success rates using highly active antiretroviral treatment (HAART) 
in people living with HIV/AIDS in Africa can be as high as those achieved in Western settings. \line \line {\b Roche 
Policies in Least Developed Countries } \line No patents for any of Roche medicines - 
across 
all disease areas - will be filed in the world\u8217?s Least Developed Countries (LDCs), as defined by the 
UN. Roche will not file patents on new HIV/AIDS medicines in Least Developed Countries or sub-Saharan 
Africa. Roche will not take action in these countries against the sale or manufacture of generic versions 
of HIV medicines for which Roche still holds patents. Generic versions of such HIV medicines can therefore 
be produced in LDCs and sub-Saharan Africa without the need for a voluntary or compulsory licence. \line \line Roche 
makes its HIV protease inhibitors \u8211? Invirase (saquinavir) and Viracept (nelfinavir) available at no 
profit prices for direct supplies from Roche Basel to LDCs and sub-Saharan Africa. \line \line Roche 
no profit pricing and patent policies apply to Cambodia and to approximately two thirds of all people 
living with HIV/AIDS in the world.\line Through its AmpliCare program Roche has been supplying 
HIV viral load tests at the lowest possible price to sub-Saharan Africa, South Africa, and countries 
defined by the United Nation as \u8216?least developed\u8217?. AmpliCare focuses on the complete continuum of care 
\u8211? from testing to monitoring to education \u8211? and works to optimize efforts on a region-by-region basis. 
It includes flexible pricing and support of major government and private programs. Capping it off is 
an education program to ensure that local doctors and nurses are fully informed on the latest advances 
in HIV/ AIDS care. \line \line {\b Roche in HIV} \line Roche 
has been committed 
since 1985 to groundbreaking HIV research and development of innovative new HIV drugs and diagnostic 
technology. Roche is a founding partner of the Accelerating Access Initiative to increase access to 
HIV care in the world's Least Developed Countries and sub-Saharan Africa. For more information on Roche 
policy and pricing of HIV protease inhibitors for these regions and research in HIV, see www.roche-hiv.com (http://www.roche-hiv.com).\line \line {\b About 
Roche} \line Headquartered in Basel, Switzerland, Roche is one of the world\u8217?s leading 
research-intensive healthcare groups. Its core businesses are pharmaceuticals and diagnostics. As a 
supplier of innovative products and services for the prevention, diagnosis and treatment of disease, 
the Group contributes on a broad range of fronts to improving people\u8217?s health and quality of life. Roche 
is number one in the global diagnostics market, the leading supplier of pharmaceuticals for cancer and 
transplantation and a market leader in virology. In 2003 the Pharmaceuticals Division generated 19.8 
billion Swiss francs in prescription drug sales, while the Diagnostics Division posted sales of 7.4 
billion Swiss francs. Roche employs roughly 65,000 people in 150 countries and has R&D agreements 
and strategic alliances with numerous partners, including majority ownership interests in Genentech 
and Chugai.\line \line {\b The National Center for HIV/AIDS, STD and Dermatology, 
Ministry of Health, Cambodia} \line The National Center for HIV/AIDS, STD and Dermatology 
(NCHADS) is the institution within the Cambodian Ministry of Health responsible for the planning, conduct 
and evaluation of government health sector HIV/AIDS and STI policy and programs. \line \line {\b National 
Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Australia} \line NCHECR 
is Australia\u8217?s leading agency in HIV-related clinical research. It has responsibility for the coordination 
of Australia\u8217?s national surveillance system for HIV/AIDS and for the conduct of HIV therapeutic trials. 
In addition to collaborations in Cambodia, it is involved in HIV research and programs throughout the 
Asia Pacific region. \line {\pard\f0\li0\ri0\sa360\sl360\fs18 \line All trademarks used or mentioned 
in this release are legally protected.\par}\line \line An open day 
for media is being scheduled at the clinic in March, 2005. Please contact Cendrine Banerjee-Quetel (cendrine.banerjee-quetel@ketchum.com) 
if you would like further information.\line \line {\b Additional information:} \line - 
National Centre (http://www.med.unsw.edu.au/nchecr) in HIV Epidemiology and Clinical Research at the University of New 
South Wales, 
Australia: www.med.unsw.edu.au/nchecr/ \line - Cambodian Ministry of Health (http://www.cambodia.gov.kh/unisql1/egov/english/ministry.detail.html?link=9): 
www.cambodia.gov.kh/unisql1/egov/english\line - Sustainable Development at Roche: 
www.roche.com/home/sustainability.htm 
\line - Roche Pharmaceuticals in HIV/AIDS (http://www.roche-hiv.com): www.roche-hiv.com \line - 
Roche Diagnostics AmpliCare program: http://www.roche.com/pages/downloads/sustain/pdf/rochehivbro_e.pdf 
\line \line {\pard\f0\li0\ri0\sa360\sl360\fs18 References:\line 1 \u160?UNAIDS 2004 Report 
on the Global AIDS Epidemic, June 2004, page 28\line 2 \u160?WHO/UNAIDS Epidemiological fact 
sheets on HIV/AIDS and sexually transmitted infections \u8211? Cambodia, 2004 update\par}\par}
{\pard \par}
{\pard\sb180\f1\fs22 {\b F. Hoffmann-La Roche Ltd}\line 4070 Basel\line Switzerland \par}
{\pard\sb180\f1\fs22 Corporate Communications\line Roche Group Media Relations \par}
{\pard\sb180\f1\fs22 Tel. +41 61 688 88 88\line Fax +41 61 688 27 75\line www.roche.com \par}
}